Omios Biologics

What Omios Biologics does

Omios Biologics is a privately held, pre-clinical biotechnology company founded in 2023 and headquartered in Oakland, California. The company develops biomarker-guided oncolytic virus (OV) immunotherapies for cancer treatment, built on a proprietary patented platform based on a modified vaccinia virus (VACV). The technology exploits cancer cells' deficiencies in innate immune response through targeted viral gene deletions (E3L, D10), enabling selective replication in cancer cells while sparing healthy tissue. The company describes its approach as the first OV platform with a built-in biomarker for patient selection and a paradigm shift from attenuation-based to mutation-specific targeting. Omios pursues three programs from a shared viral backbone: OV therapy for solid tumors, a vaccine platform for cancer and infectious diseases, and a gene delivery platform for systemic therapeutic payload delivery.

The platform is designed for systemic intravenous delivery, targeting both primary tumors and metastases, and is intended to combine safely with standard-of-care therapies and immune checkpoint inhibitors without added toxicity. The company is advancing toward first-in-patient clinical trials through strategic collaborations with the Beckman Research Institute of City of Hope (solid tumor research, announced March 2026) and XDemics Corporation (manufacturing optimization via HDCR technology with a projected 50% production cost reduction, announced April 2026). The leadership team combines deep scientific pedigree — Scientific Co-founder Prof. Ian Mohr (NYU) developed the genetic backbone of T-Vec/Imlygic, the first FDA/EMA-approved oncolytic virus, and Founder/CEO Aldo Pourchet developed the predecessor T-Stealth platform later acquired by Janssen via BeneVir Biopharm — with complementary business and computational leadership.

Omios is pre-revenue with no disclosed funding rounds, no paying customers, and no pricing in place. The intended revenue model is licensing, royalties, and biopharma partnerships upon regulatory approval. Initial focus indications are breast, liver, and colon cancers, with research expanded to include lung, gastrointestinal, and pancreatic cancers. Distribution is planned through clinical trial sites initially, followed by biopharma licensing partnerships for global commercialization.

Name

Omios Biologics

Legal name

Omios Biologics

Website

https://omiosbio.com

Company type

Private

Founded year

2023

Operating status

Operating

Short description

Omios Biologics is a pre-clinical biotech developing biomarker-guided oncolytic virus immunotherapies based on a proprietary modified vaccinia virus platform for selective treatment of solid tumors, including breast, liver, colon, lung, GI, and pancreatic cancers.

Ownership category

akta.pro rank

Product category

Cancer Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Oncolytic virus therapy
• Cancer immunotherapy
• Biomarker-guided therapy
• Modified vaccinia virus
• Solid tumor treatment

Headquarters

HQ city

Oakland Mills

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations

Revenue model

1. Oncolytic Virus Therapeutics: Pre-revenue biotech company developing proprietary oncolytic virus immunotherapies for cancer treatment. Revenue generation will come from licensing, partnerships, and eventual commercialization of therapeutic products upon regulatory approval.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Omios Biologics develops a proprietary biomarker-guided oncolytic virus immunotherapy platform based on a modified vaccinia virus (VACV) engineered to selectively destroy cancer cells while sparing healthy tissues. The platform supports three programs: an oncolytic virus therapy program for direct cancer cell destruction, a vaccine platform for cancer and infectious disease applications, and a gene delivery platform for systemic therapeutic payload delivery to solid tumors. Products are in pre-clinical development and target hard-to-treat solid tumors such as breast, lung, GI, and pancreatic cancers.

Product overview

Omios Biologics offers a unified platform of oncolytic virus immunotherapies built on proprietary modified vaccinia virus (VACV) technology. The portfolio consists of three core programs: the OV Platform for direct cancer cell destruction and immune stimulation, the Vaccine Platform for cancer and infectious disease applications, and the Gene Delivery Platform for systemic therapeutic payload delivery to solid tumors. All three programs share the same modified vaccinia virus backbone engineered with cancer-selective mutations, with the OV Platform serving as the primary offering. The platform is designed for systemic intravenous delivery and combines with standard of care treatments and immune checkpoint inhibitors.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncolytic Virus (OV) Therapy Platform A proprietary biomarker-guided oncolytic virus immunotherapy platform based on modified vaccinia virus (VACV) designed to selectively destroy cancer cells while directing the body's natural defenses against cancer. It exploits cancer cells' deficiencies in innate immune response through deletion of viral genes like D10 and E3L, and supports systemic intravenous delivery with combination use alongside standard of care and immune checkpoint inhibitors.
• Vaccine Platform for Cancer and Infectious Diseases A platform utilizing modified vaccinia virus technology to create vaccines for both cancer and infectious diseases, leveraging the same viral engineering approach and gene-deletion architecture as the company's OV platform.
• Gene Delivery Platform A platform utilizing modified vaccinia virus for systemic gene delivery to treat solid tumors, enabling therapeutic payload delivery and enhanced oncolytic effects via systemic intravenous administration.

Quantifiable outcome

• At least 50% reduction in production costs projected through partnership with XDemics Corporation
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• XDemics CorporationcoreStrategic or Co-development Partner · 23 April 2026Multi-year strategic collaboration to optimize production of next-generation oncolytic virus therapeutics for cancer treatment. Combines Omios' cancer-targeted OV platform with XDemics' high-density bioproduction platform (HDCR technology). Aims to address tumor selectivity and insufficient viral yields - two historical limitations in the oncolytic virus field. Projects at least 50% reduction in production costs to make advanced OV therapies more accessible to broader patient populations.
• City of Hope (Beckman Research Institute)coreStrategic or Co-development Partner · 17 March 2026Material Transfer Agreement to conduct advanced studies evaluating Omios' proprietary biomarker-guided, non-attenuated oncolytic virus immunotherapy platform in solid tumor models. Research led by Dr. Stephen J. Forman focuses on breast, lung, GI, and pancreatic cancers. Represents a key step in Omios' strategy toward first-in-patient clinical trials. City of Hope provides expertise in translational research and vaccinia oncolytic virus manufacturing.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Replimune: Replimune develops a portfolio of engineered oncolytic virus immunotherapies (RP1, RP2, RP3) for solid tumors. It is the most directly comparable pure-play oncolytic virus company, sharing Omios' focus on engineered viral platforms for solid tumor indications and combination with immune checkpoint inhibitors.
• Vyriad: Vyriad is a clinical-stage biotech developing engineered oncolytic vesicular stomatitis virus (VSV) and measles virus immunotherapies for cancer. Its focus on engineered viral vectors for systemic and intratumoral delivery directly parallels Omios' modified vaccinia virus approach.
• Candel Therapeutics: Candel Therapeutics develops oncolytic viral immunotherapies, including its enadenotucirev-derived platform, for cancer treatment. It is a closely comparable peer given its engineered OV approach and focus on solid tumor immunotherapy combinations.
• Turnstone Biologics: Turnstone Biologics develops oncolytic virus immunotherapies designed to combine viral oncolysis with tumor-specific immune activation. It is a relevant direct peer based on its engineered OV approach and cancer immunotherapy focus.
• Istari Oncology: Istari Oncology is developing talimogene laherparepvec-related and next-generation oncolytic virus approaches including PVSRIPO. It operates in the same engineered OV space targeting solid tumors, making it a relevant peer.
• SillaJen (Pexa-Vec / JX-594): SillaJen has led the clinical development of Pexa-Vec, a modified vaccinia virus-based oncolytic immunotherapy. Its use of an engineered VACV backbone for oncology directly mirrors Omios' core technology platform.
• DNAtrix: DNAtrix is a clinical-stage company developing oncolytic virus immunotherapies (DNX-2401, DNX-2440) primarily for brain tumors and other solid tumors. It shares Omios' mission of engineered viral immunotherapy platforms for oncology.

Emerging players

• Targovax: Targovax develops oncolytic viruses for solid tumors, with a focus on immune-stimulatory approaches that combine with checkpoint inhibitors. It is a relevant emerging peer given its engineered OV programs in clinical development.

Others

• BeneVir Biopharm (historical): BeneVir Biopharm Inc. was the prior owner of the T-Stealth technology (now part of Janssen via acquisition). It represents the direct scientific lineage of Omios' founder and is highly relevant as a comparable in the modified vaccinia virus OV space, though no longer operating independently.

Broad incumbents

• Amgen (T-Vec/Imlygic): Amgen commercializes T-Vec/Imlygic, the first FDA-approved oncolytic virus therapy for melanoma. As the established benchmark in the OV category, Amgen defines the competitive context Omios must compete against or differentiate from.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/omios-biologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omios Biologics